The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt by studies that question the safety of the devices.
Now the company has been told by a court that it must pay $431 million to a doctor who holds patents on certain IP in BSX drug-coated stents. According to the AP, Boston Scientific "plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal."
With the company’s luck that is not likely.
BSX shares trade just above $12, near their 52-week low and down from the period high of $17.32.
Douglas A. McIntyre
ro
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
